C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer

• Published in: Molecular cancer therapeutics 2006-11, Vol.5 (11), p.2919-2930
• Main Authors: Evans, Elizabeth E, Henn, Alicia D, Jonason, Alan, Paris, Mark J, Schiffhauer, Linda M, Borrello, Melinda A, Smith, Ernest S, Sahasrabudhe, Deepak M, Zauderer, Maurice
• Format: Article
• Language: English
• Subjects: Amino Acid Sequence; Animals; Antigens, Neoplasm - genetics; Antigens, Neoplasm - metabolism; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; DNA, Complementary - metabolism; ERBB2; Female; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Mapping and Cloning of Cancer Genes; Molecular Sequence Data; Neoplasm Proteins - genetics; Neoplasm Proteins - metabolism; New targets; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Tumor Cells, Cultured; Tumor markers and detection of metastasis
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.MCT-06-0389

Identification of shared tumor-specific targets is useful in developing broadly applicable therapies. In a study designed to identify genes up-regulated in breast cancer, a cDNA clone corresponding to a novel gene C35 ( C17orf37 ) was selected by representational difference analysis of tumor and normal human mammary cell lines. Abundant expression of C35 transcript in tumors was confirmed by Northern blot and real-time PCR. The C35 gene is located on chromosome 17q12, 505 nucleotides from the 3′ end of the ERBB2 oncogene, the antigenic target for trastuzumab (Herceptin TM ) therapy. The chromosomal arrangement of the genes encoding C35 and ERBB2 is tail to tail. An open reading frame encodes a 12-kDa protein of unknown function. Immunohistochemical analysis detected robust and frequent expression of C35 protein, including 32% of grade 1 and 66% of grades 2 and 3 infiltrating ductal carcinomas of the breast (in contrast to 20% overexpressing HER-2/ neu ), 38% of infiltrating lobular carcinoma (typically HER-2/ neu negative), as well as tumors arising in other tissues. C35 was not detected in 38 different normal human tissues, except Leydig cells in the testes and trace levels in a small percentage of normal breast tissue samples. The distinct and favorable expression profile of C35 spanning early through late stages of disease, including high frequency of overexpression in various breast carcinoma, abundant expression in distant metastases, and either absence or low level expression in normal human tissues, warrants further investigation of the relevance of C35 as a biomarker and/or a target for development of broadly applicable cancer-specific therapies. [Mol Cancer Ther 2006;5(11):2919–30]